Abstract Gestational diabetes mellitus (GDM) is characterised by maternal peripheral insulin resistance and inflammation. Sterile inflammation and bacterial infection are key mediators of this enhanced inflammatory response. Adenosine monophosphate (AMP)-activated kinase (AMPK), which is decreased in insulin resistant states, possesses potent pro-inflammatory actions. There are, however, no studies on the role of AMPK in pregnancies complicated by GDM. Thus, the aims of this study were (i) to compare the expression of AMPK in adipose tissue and skeletal muscle from women with GDM and normal glucose-tolerant (NGT) pregnant women; and (ii) to investigate the effect of AMPK activation on inflammation and insulin resistance induced by the bacterial endotoxin lipopolysaccharide (LPS) and the pro-inflammatory cytokine IL-1β. When compared to NGT pregnant women, AMPKα activity was significantly lower in women with GDM as evidenced by a decrease in threonine phosphorylation of AMPKα. Activation of AMPK, using two pharmacologically distinct compounds, AICAR or phenformin, significantly suppressed LPSor IL-1β-induced gene expression and secretion of proinflammatory cytokine IL-6, the chemokines IL-8 and MCP-1, and COX-2 and subsequent prostaglandin release from adipose tissue and skeletal muscle. In addition, activators of AMPK decreased skeletal muscle insulin resistance induced by LPS or IL-1β as evidenced by increased insulin-stimulated phosphorylation of IRS-1, GLUT-4 expression and glucose uptake. These findings suggest that AMPK may play an important role in inflammation and insulin resistance.
type 2 diabetes and cardiovascular disease later in life [5] . The health care and fiscal costs are enormous [12] .
Inflammation is a central feature of pregnancies complicated by GDM [26] . Pro-inflammatory cytokines and bacterial infections are recognised as key mediators of this inflammation [19] . A myriad of pro-and anti-inflammatory cytokines, secreted from pregnant adipose tissue [18, 19] and skeletal muscle [18] , are thought to play a central role in the pathogenesis and/or progression of GDM. Pregnancies complicated by GDM are also associated with maternal skeletal muscle insulin resistance [4] . The resultant increase in nutrient availability increases the risk of fetal fat accretion which predisposes the offspring of women with GDM to childhood obesity and later adult disease [5] . Little, however, is known about the cellular mechanisms responsible for this altered skeletal muscle insulin resistance and/or enhanced inflammation.
In non-pregnant tissues, adenosine monophosphate (AMP)-activated protein kinase (AMPK) has been implicated in modulating glucose metabolism and acute inflammatory reactions. AMPK is a serine/ threonine protein kinase that consists of three heterogenic subunits, a catalytic (α) subunit and two regulatory subunits (β and γ); all of which exist in at least two isoforms. There is much evidence to demonstrate that AMPK regulates skeletal muscle glucose metabolism [9] . However, recent data indicate that activation of AMPK might also be a useful strategy for beneficial regulation of the inflammatory responses. For example, in vitro, activation of AMPK is associated with inhibition of cytokine production in lipopolysaccharide (LPS)-stimulated murine neutrophils [34] ; LPS-stimulated primary astrocytes, microglia and peritoneal macrophages [8] ; and IL-1β-stimulated adipose tissue and skeletal muscles [21] . In vivo, activation of AMPK has been shown to inhibit the production of pro-inflammatory mediators in serum and their expression in the central nervous system of rats injected with a sublethal dose of LPS [8] . Enhanced activation of AMPK also resulted in diminished severity of LPS-induced acute lung injury in mice [34] .
Diminished AMPK activity or impairment of its activation has been observed in skeletal muscle of individuals with obesity and diabetes [28] .
Similarly, in adipose tissue, AMPK activity is decreased in morbidly obese individuals who are insulin resistant than in comparably obese people who are insulin sensitive [31] . Recently, we have published that AMPK activity is lower in skeletal muscle obtained from women with GDM [1] . However, a limitation of these studies was that all women were obese and treated with insulin for optimal glucose control. In addition, there are no studies that have determined the effect of GDM on the expression of AMPK in human pregnant adipose tissue. Thus, the aim of this study was to determine the AMPK protein expression in omental adipose tissue and skeletal muscle from nonobese women with diet-controlled GDM and compare them to body mass index (BMI)-matched normal glucose-tolerant (NGT) women. In addition, the effect of AMPK activators on adipose tissue and skeletal muscle inflammation and skeletal muscle insulin resistance induced by endotoxemia (i.e. LPS) or the pro-inflammatory cytokine IL-1β was also determined from NGT women. In this study, two well-described AMPK activators were used: AICAR (5-amino-1-β-Dribofuranosylimidazole-4-carboxamide), an analogue of adenosine that enters cells and stimulates AMPK [22] , and an antidiabetic drug from the biguanide class, phenformin, which activates AMPK by increasing cytosolic AMP concentration [33] .
Materials and methods

Tissue collection and preparation
Human omental adipose tissue and skeletal muscle (pyramidalis) described in this study were obtained (with the Research Ethics Committee of Mercy Health approval) from consenting women who delivered healthy, singleton infants at term (>37 weeks gestation). Indications for Caesarean section were breech presentation and/or previous Caesarean section. Tissues were obtained and processed within 15 min of delivery.
Omental adipose tissue (n = 12 patients) and skeletal muscle (n = 12 patients) were obtained from non-obese NGT women and BMI-matched women with GDM. The clinical details of the patients used in this study are detailed elsewhere [20] . Women with any underlying medical conditions such as pre-existing diabetes, asthma, polycystic ovarian syndrome, preeclampsia and macrovascular complications were excluded. Women with GDM were diagnosed according to the criteria of the Australasian Diabetes in Pregnancy Society (ADIPS) by either a fasting venous plasma glucose concentrations of ≥5.5 mmol/l glucose and/or ≥8.0 mmol/l glucose 2 h after a 75-g oral glucose load at approximately 28 weeks gestation. All women with GDM were managed by diet alone. All pregnant women were screened for GDM, and women participating in the normal group had a negative screen. Tissues were thoroughly washed in ice-cold PBS to remove any blood. Dissected fragments were stored at −80°C until assayed as detailed below.
Tissue explant culture
Tissue explants were performed to determine the effect of AMPK activators on inflammation in pregnant adipose tissue and skeletal muscle. For these studies, adipose tissue and skeletal muscle were obtained from non-obese NGT pregnant women, and tissue explants were performed as previously described [18, 19] . Briefly, adipose tissue and skeletal muscle were finely diced and placed in DMEM at 37°C in a humidified atmosphere of 21 % O 2 and 5 % CO 2 for 1 h. Tissues were blotted dry on sterile filter paper and transferred to 24-well tissue culture plates (100 mg for adipose tissue and 50 mg for skeletal muscle). The explants were incubated in 1 ml DMEM containing 100 U/ml penicillin G and 100 μg/ml streptomycin. Tissues were incubated in the absence or presence of 2 mM AICAR (AdooQ BioScience; Sapphire Bioscience, NSW, Australia) or 1 mM phenformin (Cayman Chemical Co; Sapphire Bioscience, NSW, Australia) for 60 min before the addition of 10 μ g/ml LPS (derived from Escherichia coli 026:B6; Sigma-Aldrich; St. Louis, MO, USA) or 1 ng/ml IL-1β (PeproTech; Rocky Hill, NJ, USA) for 20 h. After final incubation, tissue and media were collected separately and stored at −80°C for further analysis as detailed below. The concentrations of AICAR and phenformin were based on previous studies in non-gestational tissues [8, 34] . Each treatment was performed on tissues obtained from at least five patients.
To assess the effect of AMPK activators on the insulin signalling pathway, skeletal muscle explants were performed as detailed above; however, after 20 h incubation, tissues were incubated with 0.1 μM insulin for 30 min. After final incubation, tissue was collected and assessment of insulin signalling proteins performed by qRT-PCR or Western blotting as detailed below. Each treatment was performed on tissues obtained from four patients.
Glucose uptake
Skeletal muscle explants were performed as detailed above and glucose uptake was performed as previously described [19] . Briefly, after final incubation with treatment, tissues were preincubated in the absence or presence of 20 μM cytochalasin B in Krebs buffer for 5 min. 2-Deoxy-D-glucose (2DG) uptake was measured by adding 3 μCi/ml [ 14 C]-2DG (Perkin Elmer) and 1 mM 2DG to Krebs buffer containing 0.5 % bovine serum albumin (BSA; fatty acid free) and 0.1 μM insulin for 20 min. Tissues were then collected and washed three times in PBS, blotted dry on filter paper and the solubilised for 4 h in 0.5 ml 1 M NaOH at 60°C. Tissues were neutralised with 0.5 ml 1 M HCl and then centrifuged at 15,000×g for 5 min to pellet insoluble material. The supernatant was transferred to a vial containing 3 ml of liquid scintillation fluid. All samples were counted for radioactivity in a liquid scintillation counter. GLUT-specific glucose uptake was measured by subtracting values for [ 14 C]-2DG uptake in the presence of 20 μM cytochalasin B. Fold change was calculated relative to LPS or IL-1β, which was set at 1. Glucose uptake was performed on tissues obtained from four patients.
Western blotting
Tissue lysates and Western blotting were prepared as previously described [20] . Twenty micrograms of protein was separated on polyacrylamide gels (Bio-Rad Laboratories; Gladesville, NSW, Australia) and transferred to PVDF. Protein expression was identified by comparison with the mobility of protein standard. Blots were incubated with 1 μg/ml rabbit polyclonal phosphorylated Thr172 AMPKα (sc-33524; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 1 μg/ml mouse monoclonal AMPKα1/2 (sc-74461; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1 μg/ml rabbit polyclonal phosphorylated (Tyr1229) IRS-1 (sc-17202; Santa Cruz Biotechnology; Santa Cruz, CA, USA), 1 μg/ml rabbit polyclonal IRS-1 (sc-560; Santa Cruz Biotechnology; Santa Cruz, CA, USA), 2 μg/ml rabbit p o l y c l o n a l G L U T-4 ( s c -7 9 3 8 ; S a n t a C r u z Biotechnology; Santa Cruz, CA, USA) diluted in blocking buffer (5 % BSA in TBS with 0.05 % Tween-20) for 16 h at 4°C. Membranes were viewed and analysed using the XRS ChemiDoc system (BioRad Laboratories; Gladesville, NSW, Australia). Semiquantitative analysis of the relative density of the bands in Western blots was performed using Image Lab v3 analysis software (Bio-Rad Laboratories; Gladesville, NSW, Australia). For Figs. 1 and 2, the levels of phosphorylated AMPKα were normalised to the levels of total AMPKα1/2 and fold change was calculated relative to the NGT group. For the explant studies, the levels of phosphorylated IRS-1 were normalised to the levels of total IRS-1 while the levels of GLUT-4 were normalised to the levels of β-actin (1:20,000; A5316; SigmaAldrich; St. Louis, MO, USA). Fold change was calculated relative to LPS or IL-1β, which was set at 1.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from tissues using TRIsure™ according to manufacturer's instructions (Bioline; Alexandria, NSW, Australia). RNA concentration and purity were measured using a NanoDrop ND1000 spectrophotometer (Thermo Fisher Scientific; Scoresby, Vic, Australia). RNA was converted to cDNA the Tetro cDNA synthesis kit (Bioline; Alexandria, NSW, Australia) according to the manufacturer's instructions. The cDNA was diluted 50-fold, and 4 μl of this was used to perform RT-PCR using SensiFAST™ SYBR (Bioline; Alexandria, NSW, Australia) and 100 nM of pre-designed and validated QuantiTect primers (Qiagen; Chadstone Centre, Vic, Australia). The RT-PCR was performed using a CFX384 Real-Time PCR detection system (BioRad Laboratories; Gladesville, NSW, Australia). Average gene Ct values were normalised to the average 18S Ct values of the same cDNA sample. Fold differences were determined using the comparative Ct method. For the explant studies, there was a large variability in the response to LPS or IL-1β which is normal for tissues derived from different patients. Thus, fold change was calculated relative to LPS or IL-1β, which was set at 1.
Cytokine and prostaglandin immunoassays
The release of MCP-1, IL-6 and IL-8 was performed by sandwich ELISA according to the manufacturer 's instructions (Life Technologies; Mulgrave, Vic, Australia). The release of PGE 2 into the incubation medium was assayed using a commercially available competitive enzyme immunoassay kit according to the manufacturer's specifications (Kookaburra Kits from Sapphire Bioscience; Waterloo, NSW, Australia). The limit of detection of the PGE 2 assay was 16 pg/ml. All data were corrected for total protein and expressed Fig. 1 AMPKα activity is lower in adipose tissue and skeletal muscle from GDM women. a Omental adipose tissue and b skeletal muscle were obtained from non-obese women with NGT (n=6 patients per group) and diet-controlled GDM (n=6 patients per group) at the time of term Caesarean section. Phosphorylation of AMPKα at Thr172 (p-AMPKα) was analysed by immunoblotting and normalised to total AMPKα1/2 protein expression. The fold change was calculated relative to NGT and data is displayed as mean±SEM. *P<0.05 vs. NGT (Student's t test). Representative Western blot from two NGT and two GDM patients is also shown as either picogram or nanogram per milligram protein. The protein content of tissue homogenates was determined using BCA protein assay (Thermo Fisher Scientific; Scoresby, Vic, Australia), using BSA as a reference standard, as previously described [18] . The calculated interassay and intraassay coefficients of variation (CV) were all less than 10 %.
Statistical analysis
Statistics was performed on the normalised data unless otherwise specified. All statistical analyses were undertaken using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). For two sample comparisons, an unpaired Student's t test was used to assess statistical significance between normally distributed data; otherwise, the nonparametric Mann-Whitney U (unpaired) or the Wilcoxon (matched pairs) tests were used. For all other comparisons, the homogeneity of data was assessed by the Bartlett test, and when significant, the data were logarithmically transformed before further analysis using a one-way ANOVA (using LSD correction to discriminate among the means). Statistical significance was ascribed to P value <0.05. Data were expressed as mean±standard error of the mean (SEM). 
Results
AMPKα activity is decreased in adipose tissue and skeletal muscle from women with GDM Adipose tissue and skeletal muscle was obtained from non-obese women with NGT or diet-controlled GDM. Demographic data of all participants involved in this study are detailed elsewhere [20] . There was no difference in maternal pre-pregnancy BMI, maternal BMI at delivery, maternal age, gestational weight gain, fetal birthweight or gestation age at delivery. Fasting, 1-and 2-h plasma glucose during the antenatal OGTT were significantly higher in women with GDM when compared to NGT pregnant women.
Western blotting was used to determine the expression of total AMPKα and AMPKα phosphorylated at Thr172 (p-AMPKα). The protein expression of p-AMPKα was significantly lower in adipose tissue (Fig. 1a) and skeletal muscle (Fig. 1b) from women with GDM when compared to BMImatched NGT women.
Activators of AMPK decrease LPS-induced pro-inflammatory cytokines and chemokines in adipose tissue and skeletal muscle
The above studies show that AMPK activity is decreased in adipose tissue and skeletal muscle of women with GDM. Thus, the next aim was to determine the effect of the AMPK activators on TLR4-induced expression and secretion of proinflammatory cytokines, chemokines and adhesion molecules. Of note, in all subsequent experiments in this study, adipose tissue and skeletal muscle were obtained from NGT pregnant women and stimulated with either LPS or IL-1β as a model of GDM. The data for adipose tissue is presented in Fig. 2 while the data for skeletal muscle is presented in Fig. 3 . In both tissues, treatment with LPS induced a significant increase in the mRNA expression and release of IL-6, IL-8 and MCP-1. Treatment with the AMPK activators AICAR or phenformin significantly suppressed LPS-induced cytokine and chemokine expression and secretion. Of note, there was no effect of AMPK activators on cytokine release under basal conditions (data not shown).
Activators of AMPK decrease IL-1β-induced pro-inflammatory cytokines and chemokines in adipose tissue and skeletal muscle
The data for adipose tissue are presented in Fig. 4 while the data for skeletal muscle are presented in Fig. 5 . As expected, IL-1β significantly increased IL-6, IL-8 and MCP-1 gene expression and release from both adipose tissue and skeletal muscle. Co-incubation with AICAR or phenformin significantly attenuated IL-1β-stimulated cytokine and chemokine gene expression and secretion.
Activators of AMPK decrease LPS-and IL-1β-induced COX-2 expression and PGE 2 production in adipose tissue Our previous studies have shown that LPS and IL-1β can induce COX-2 expression and subsequent prostaglandin release from adipose tissue [20] . COX-2 and the prostaglandin PGE 2 have been shown to contribute to the pathophysiology of diabetes [24] . Therefore, the next aim was to determine the effect of AMPK on the COX-2-prostaglandin pathway in adipose tissue is presented in Fig. 6 . As expected, LPS and IL-1β significantly induced COX-2 expression (Fig. 6a, c) and PGE 2 secretion (Fig. 6b, d ). Co-incubation with AICAR or phenformin significantly suppressed both LPS-and IL-1β-induced activation of the COX-2-prostaglandin pathway. Of note, there was no effect of LPS or IL-1β with or without AMPK activators on COX-1 expression (data not shown).
Activators of AMPK improve LPS-and IL-1β-induced defects in the insulin pathway
Skeletal muscle insulin resistance is a key feature of pregnancies complicated by GDM [4] . Thus, the final aim of this study was to determine the effect of AMPK activation on insulin signalling in the presence of LPS or IL-1β. Both LPS (Fig. 7) and IL-1β (Fig. 8) significantly attenuated phosphorylated IRS-1 protein expression (Figs. 7a and 8a) , GLUT-4 protein expression (Figs. 7b and 8b) and 2DG uptake (Figs. 7c and 8c) . In contrast, co-incubation with AICAR and phenformin in skeletal muscle and adipose tissues treated with either LPS or IL-1β restored phosphorylated IRS-1 (Figs. 7a and 8a ) and GLUT-4 protein expression (Figs. 7b and 8b ) and 2DG uptake (Figs. 7c and 8c ) to basal levels.
Discussion
A novel finding of this study is that AMPKα activity is decreased in omental adipose tissue and skeletal muscle obtained from women with diet-controlled GDM when compared to BMImatched NGT women. Moreover, activation of AMPKα could efficiently prevent the expression and release of pro-inflammatory mediators in omental adipose tissue and skeletal muscle that were stimulated with TLR4 ligand and bacterial product LPS and the pro-inflammatory cytokine IL-1β. AMPK also improved glucose metabolism in skeletal muscle stimulated with LPS and IL-1β. Collectively, these results show the importance of AMPK activation in improving inflammation and insulin resistance in pregnant adipose tissue and skeletal muscle.
In this study, threonine phosphorylation of AMPKα was lower in adipose tissue and skeletal muscle obtained from women with GDM who were managed by diet when compared to BMI-matched NGT pregnant women, thus suggesting decreased AMPKα activity in pregnant GDM tissues. Of note, and in agreement of these findings, we have also recently reported lower threonine phosphorylation of AMPKα in skeletal muscle of obese GDM who were managed by insulin during pregnancy [1] . These findings are also in line with studies in nonpregnant individuals and in experimental animal models of diabetes. For example, studies in skeletal muscle [28] or adipose tissue [31] of obese, insulin-resistant humans show decreased AMPK activity or impaired activation than in comparably obese people who are insulin sensitive. Moreover, reduced AMPK activity has been observed in skeletal muscle of rodents with the metabolic syndrome, including Zucker diabetic fatty rats [32] and ob/ob mice [32] . Collectively, these findings show that insulin-resistant individuals, regardless of BMI, have decreased AMPK activity. The upstream mediators involved in the decrease in AMPKα in GDM adipose tissue and skeletal muscle are not known. However, a number of diabetes-related stimuli including high glucose, oxidative stress, inflammation and fatty acids have been shown to diminish AMPK activity in rodents in vivo [27] . Nevertheless, the findings of this study suggest that AMPK may thus play a role in the pathophysiology of insulin resistance that is independent of obesity.
It should be noted that a strong point of this study is the well-defined study population that was used for assessment of AMPK expression. Patients were excluded for maternal or clinical factors which may influence the maternal inflammatory profile such as asthma, preeclampsia, pre-existing diabetes, hypertension and smoking. In addition, tissues were obtained from women at the time of term Caesarean section in the absence of labour which is an inflammatory state [16] . Importantly, and in addition to including both lean and obese patients, patients were matched for gestational weight gain. This is important as fasting and exercise have been reported to activate AMPK [2] . A further strength of this study was the inclusion of tissues from GDM women controlled by diet therapy only ensuring that the changes in AMPK expression were not due to insulin therapy.
In non-pregnant tissues, activation of AMPK has been shown to reduce inflammation in response to a number of stimuli including LPS and IL-1β [8, 34] . GDM is associated with enhanced inflammation [19] . Both sterile inflammation and bacterial infection are thought to play a role in mediating this inflammatory response. TNF-α induces the secretion of proinflammatory cytokine expression in human placenta, and adipose tissue and skeletal muscle from pregnant women [18] . Similarly, bacterial products such as LPS, Fig. 5 Effect of AMPK activators on IL-1β-induced pro-inflammatory cytokines and chemokines in skeletal muscle. Human skeletal muscle from NGT pregnant women was incubated with 1 ng/ml IL-1β in the absence or presence of 2 mM AICAR or 1 mM phenformin (Phen) for 20 h (n=5 patients). a-c Gene expression for IL-6, IL-8 and MCP-1 was analysed by qRT-PCR. Gene expression was normalised to 18S mRNA expression and the fold change was calculated relative to IL-1β. Data displayed as mean±SEM. *P<0.05 vs. IL-1β (one-way ANOVA). d-f The incubation medium was assayed for concentration of IL-6, IL-8 and MCP-1 by ELISA. Data displayed as mean± SEM. *P<0.05 vs. IL-1β (one-way ANOVA) iE-DAP (a dipeptide present in the peptidoglycan of all Gram-negative and certain Gram-positive bacteria) and muramyl dipeptide (MDP, the minimal bioactive peptidoglycan motif common to all bacteria) can induce the gene expression and secretion of a pro-inflammatory cytokines and chemokines from human placenta, and/ or pregnant adipose tissue and skeletal muscle [18] . Given that AMPK was decreased in adipose tissue and skeletal muscle from women with GDM, it was of interest to determine if AMPK also regulates the inflammatory response in these tissues. Inflammation was induced by the TLR4 ligand bacterial endotoxin LPS and the pro-inflammatory cytokine IL-1β. In this study, the AMPK activators AICAR or phenformin decreased the expression and secretion of the pro-inflammatory cytokines IL-6, IL-8 and MCP-1 in adipose tissue and skeletal muscle stimulated with LPS or IL-1β. To our knowledge, this is the first study to report AMPK regulates inflammation in skeletal muscle and adipose tissue.
Pro-inflammatory cytokines play a myriad of roles in pregnancy and GDM. They may induce alterations in placental transport that are observed in GDM pregnancies. In keeping with this, IL-6 stimulates trophoblast fatty acid accumulation [17] and increases trophoblast System A amino acid transporter activity and expression [14] . Pro-inflammatory cytokines may also induce the peripheral insulin resistance observed in women with GDM [4] . Indeed, previous studies have shown that IL-1β, which is increased in women with GDM [19] , interferes with the insulin signalling pathway in pregnant adipose tissue [19] . Collectively, increased peripheral insulin resistance and/or increased placental nutrient transport may contribute to the fetal overgrowth and or increased fat deposition observed in infants of women with GDM [6] .
In addition to its role in regulating inflammation, AMPK may affect key metabolic processes, including skeletal muscle glucose metabolism [9] .
For example, in skeletal muscle, AMPK activation leads to increase GLUT4 transcription [35] . In insulin-resistant rats, activation of AMPK improved insulin sensitivity [13] . GLUT4 is an important transporter channel for glucose uptake by Fig. 7 Effect of AMPK activators on LPS-induced insulin resistance in skeletal muscle. Human skeletal muscle from NGT pregnant women was incubated with 10 μg/ml LPS in the absence or presence of 2 mM AICAR or 1 mM phenformin (Phen) for 20 h followed by a 30-min incubation with 0.1 μM insulin (n=4 patients). a Phosphorylated IRS-1 (pIRS-1) protein expression was normalised to total IRS-1, and the fold change was calculated relative to LPS. Data is presented as mean±SEM. *P<0.05 vs. LPS (one-way ANOVA). A representative Western blot from one patient is also shown. b GLUT-4 protein expression was normalised to β-actin, and the fold change was calculated relative to LPS. Data is presented as mean±SEM. *P<0.05 vs. LPS (one-way ANOVA). A representative Western blot from one patient is also shown. c 2DG uptake data is displayed as mean ±SEM. *P<0.05 vs. LPS (oneway ANOVA) cells. Skeletal muscle insulin resistance is a central feature of pregnancies complicated by GDM [4] . Thus, in order to further understand the role of AMPK in the pathophysiology of GDM, the effect of the AMPK activators AICAR and phenformin on the insulin signalling pathway in skeletal muscle was determined. Both IL-1β and LPS attenuated phosphorylated IRS-1 and GLUT-4 protein expression and 2DG uptake in skeletal muscle. Activation of AMPK with AICAR and phenformin subsequently rescued these defects in the insulin pathway induced by IL-1β and LPS. Thus, it is possible that impaired insulin signalling and glucose uptake in pregnant skeletal muscle may be associated with reduced or defective AMPK activation.
COX-2 and prostaglandins may also play a role in the pathophysiology of diabetes [24] . For example, in vivo studies have demonstrated inhibition of COX-2 prevents the onset of diabetes in mice [29] . Other studies have also shown COX-2 and prostaglandins to promote inflammation and, more specifically, to induce IL-6 production [11] . It has been demonstrated in hepatocytes that prostaglandins, in particular PGE 2 , blunts the insulin signalling pathway via ERK1/2-dependent serine phosphorylation of insulin receptor substrates [10] . Thus, it was also of interest to determine the role of AMPK in regulating the expression of COX-2 and the secretion of the prostaglandin PGE 2 . In keeping with studies in non-pregnant tissues [7, 25] , both LPS and IL-1β increased COX-2 mRNA expression and PGF 2α secretion in adipose tissue. This increase was significantly decrease by pre-treatment with the AMPK activators AICAR or phenformin. In concordance with this study, other studies have also shown AMPK activation is associated with decreased production of COX-2 and prostaglandins [3] . To our knowledge, however, this is the first study to report that AMPK regulates COX-2-prostaglandin pathway in adipose tissue.
Recent studies suggest a link between AMPK and IL-1β production via the inflammasome [30] . Specifically, this study found that activation of the inflammasome, using palmitate-BSA plus LPS, decreased phosphorylation of the AMPKα subunit while increasing caspase-1-mediated IL-1β production. This decrease in AMPKα and increase in IL-1β was significantly attenuated using the AMPK activator AICAR. It is interesting to note that we have recently described increased activation of the inflammasome in adipose tissue of women with GDM [19] . In these studies, we also showed that activation of the inflammasome was required to activate caspase-1-mediated IL-1β production in pregnant adipose tissue. Furthermore, treatment of pregnant adipose tissue with IL-1β resulted in a decrease in insulin-stimulated glucose uptake, suggesting that IL-1β may contribute to the pathophysiology of GDM. It is thus possible that AMPK may also regulate caspase-1 activation of IL-1β in adipose tissue.
Limitations of this study includes the effect of the AMPK activation on attenuating pro-inflammatory cytokine and insulin resistance was not assessed in adipose tissue and skeletal muscle obtained from women with GDM. In this study, LPS and IL-1β were used to model a GDM environment. Thus, the findings of this study should be interpreted with some caution. Furthermore, the pathway(s) involved in AMPK-induced suppression of inflammation and insulin sensitivity remains yet to be elucidated. Recent studies show AICAR and phenformin inhibits LPS-induced NF-κB signalling and also the transcription of NF-κB-dependent genes [15] . NF-κB is a transcription factor that regulates the expression of pro-inflammatory mediators and has been described to play an important role in the pathogenesis of diabetes and its associated complications [23] . Thus, further work is required to determine how AMPK and its activators regulate NF-κB.
In conclusion, the data presented in this study show that AMPKα activity is decreased in omental adipose tissue and skeletal muscle obtained from women with GDM. Activation of AMPK, using two pharmacologically distinct compounds, significantly suppressed LPS-or IL-1β-induced gene expression and secretion of pro-inflammatory cytokines, chemokines and prostaglandins from adipose tissue and skeletal muscle. AMPK activation also suppressed LPS-or IL-1β-induced insulin resistance and improved glucose uptake by skeletal muscle. Inflammation, by further inciting inflammation and/or inducing insulin resistance, plays a central in the pathophysiology of GDM. Thus, it would be of interest to determine the effect of AMPK activation on inflammation and glucose metabolism in animal models of GDM. Further studies on the role of AMPK in GDM are warranted.
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